Trials
Search / Trial NCT00000585

Penicillin Prophylaxis in Sickle Cell Disease (PROPS)

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999

Apply for Trial

Trial Information

Current as of January 15, 2025

Completed

Keywords

ClinConnect Summary

BACKGROUND:

For over 20 years children with sickle cell anemia have been known to have an increased susceptibility to severe bacterial infection, particularly due to Streptococcus pneumoniae. Meningitis, pneumonia and septicemia due to this organism have been recognized as the major causes of death for these children, with children under three years of age being at highest risk. The annual incidence of pneumococcal septicemia among young children with sickle cell anemia appears to have remained remarkably constant over the last two decades at approximately 10 percent. This illness can ofte...

Gender

ALL

Eligibility criteria

  • • In the Phase I trial, Black children with sickle cell anemia aged 3 months to 3 years. In the Phase II trial, children with sickle cell anemia aged five years 3 months of age and younger who had received prophylactic penicillin for at least two yea

Trial Officials

David Becton

University of Arkansas

Ann Bjornson

Gamble Institute of Medical Research

George Buchanan

University of Texas

Neil Grossman

Children's Hospital Medical Center, Cincinnati

C. Holbrook

East Carolina University School of Medicine

Rathyi Iyer

University of Mississippi Medical Center

Karen Kalinyak

Children's Hospital Medical Center, Cincinnati

Thomas Kinney

Duke University

Helen Maurer

University of Illinois at Chicago

Scott Miller

New York Health Science Center

Charles Pegelow

University of Miami

Sergio Piomelli

Columbia University

Gregory Reaman

Children's Hospital National Medical Center

Alan Schwartz

Washington University School of Medicine

Elliott Vichinsky

Children's Hospital & Medical Center

Winfred Wang

St. Jude Children's Research Hospital

Doris Wethers

St. Luke's Roosevelt Institute of Health Science

Gerald Woods

Children's Mercy Hospital Kansas City

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials